Chugai Pharmaceutical leans heavily on a small handful of best-selling medicines just as governments push for lower drug prices and look-alike rivals spread worldwide. If new treatments in its research pipeline keep slipping, the company could face a tougher stretch than many expect—even as big investments and global partnerships try to keep growth on track.Read more
Chugai leans into newer types of medicines and tighter research focus, while its close collaboration with Roche helps it reach more patients worldwide and bring therapies to market faster. The big question is whether it can keep growing as a few key drugs do most of the heavy lifting and pricing, regulation, and rising costs squeeze the business.Read more
Chugai bets that rising demand for advanced antibody medicines, plus faster research using AI and bigger manufacturing capacity, lets it sell more of its next wave of treatments worldwide. The catch is that price cuts, copycat versions of older drugs, and reliance on a partner’s overseas lineup could limit how much of that upside actually shows up.Read more
No trending discussion available.
Outstanding track record with flawless balance sheet and pays a dividend.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Chugai Pharmaceutical Co., Ltd. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
